Clinical Trial Update: Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study of Telomelysin (OBP-301) in combination with pembrolizumab for esophagogastric adenocarcinoma has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Telomelysin (OBP-301)

Snippet

Sponsor: Weill Medical College of Cornell University | Conditions: Esophagogastric Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-25